Navigation Links
A role of glucose tolerance could make the adaptor protein p66Shc a new target for cancer and diabetes
Date:2/13/2014

[TORONTO,Canada, Feb 18, 2014] A protein that has been known until recently as part of a complex communications network within the cell also plays a direct role in regulating sugar metabolism, according to a new study published on-line in the journal Science Signaling (February 18, 2014).

Cell growth and metabolism are tightly controlled processes in our cells. When these functions are disturbed, diseases such as cancer and diabetes occur. Mohamed Soliman, a PhD candidate at the Lunenfeld Tanenbaum Research Institute at Mount Sinai Hospital, found a unique role for the p66Shc adaptor protein in regulating glucose metabolism and cell growth. This report could lay the foundation for future studies to target adaptor proteins in cancer and diabetes therapy.

Proteins are functional units of cells that assemble in a precise manner to control cellular processes. Specifically, adapter proteins act as linkers or switches to fine tune cellular functions. Soliman and colleagues became interested in p66Shc adaptor protein after reading that mice deficient in it have a greatly increased lifespan and show no signs of cancer. p66Shc mice also have better glucose tolerance and are resistance to the development of obesity and diabetes. These findings prompted Soliman to take novel approaches to elucidate the mechanism to explain these findings. Briefly, Soliman explains "we found when silencing the adaptor p66Shc in cells, enhances not only glucose metabolism, but also the metabolism of and molecules involved in the making the cells building blocks, resulting in overall increased cell growth."

Thus, p66Shc may have evolved to be a switch that responds to nutrient availability. This role of p66Shc as a sensor of energy levels appears to be unique to higher level organisms explains Soliman's mentor Dr. Jim Dennis "the gene responsible for p66Shc protein expression is relatively new by evolution standards, as it is not seen in species other than vertebrates". Simply stated p66Shc acts to suppress insulin signaling and energy metabolism when glucose levels are high, as in the case of diabetes.

Mohamed Soliman is a Vanier scholar and was mentored by the late Dr. Tony Pawson whose research is credited for pioneering the field of signal transduction by first describing in the 1980's that proteins contain modular domains that allow them to interact with each other to control cellular communication. He is currently working in the laboratory of Dr. Jim Dennis, Senior Investigator at the Lunenfeld-Tanenbaum Research Institute, and a professor at the University of Toronto. This study has been done in collaboration with Dr. David Sabatini at the Massachusetts Institute of Technology.


'/>"/>

Contact: Mohamed Soliman
ma.soliman@utoronto.ca
Lunenefeld-Tanenbaum Research Institute
Source:Eurekalert  

Related biology news :

1. New study finds no reason to replace fructose with glucose
2. Glucose: Potential new target for combating annual seasonal influenza
3. Study: Metformin for breast cancer less effective at higher glucose concentrations
4. People with impaired glucose tolerance can show cognitive dysfunction
5. Lift weights to lower blood sugar? White muscle helps keep blood glucose levels under control
6. FASEB SRC announces conference: Glucose transport -- Gateway for Metabolic Systems Biology
7. Anchoring proteins influence glucose metabolism and insulin release
8. Engineers use droplet microfluidics to create glucose-sensing microbeads
9. New, designer fiber may help address fiber intolerance and ease IBS symptoms
10. Overexpression of cytoglobin gene increases neuronal hypoxic tolerance
11. Early exposure to insecticides gives amphibians higher tolerance later
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A role of glucose tolerance could make the adaptor protein p66Shc a new target for cancer and diabetes
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... , ... December 02, 2016 ... ... a consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved ... interested in supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected ... of 7.3% during the forecast period of 2016 to 2021 dominated ... accounted for the largest share of immunohistochemistry (IHC) market, by end ... , , ... market spread across 225 pages, profiling 10 companies and supported with ...
(Date:11/30/2016)... today announced the appointment of Joshua F. Coleman , ... Dr. Coleman will oversee clinical content development and curation of ... software suite empowers molecular pathologists with a seamless workflow for ... from quality control through reporting. ... , , ...
(Date:11/30/2016)... RATON, Fla. , Nov. 30, 2016 ... biotherapeutic products, is pleased to announce the addition of ... Avenue Kearney, Nebraska . The 15,200 ... business on November 29th, 2016 and brings the total ... Ileana Carlisle , BPC,s Chief Executive ...
Breaking Biology Technology: